Exenatide brand names are Byetta and Bydureon. Byetta is the twice-daily injection taken before meals, and Bydureon is the extended-release version given once a week. Both contain the same active ingredient, exenatide, and both are approved for type 2 diabetes rather than weight loss. Exenatide matters more than its current prescription numbers suggest, because it was the first GLP-1 receptor agonist ever approved, and every drug in the category that followed builds on what it started.
The exenatide brand names, side by side
There are two exenatide brand names on the US market, and the difference between them is entirely about how long the drug stays active in the body.
| Brand name | Active ingredient | How often | Doses | Approved use |
|---|---|---|---|---|
| Byetta | Exenatide (immediate release) | Twice daily, before the morning and evening meals | 5 mcg and 10 mcg | Type 2 diabetes in adults |
| Bydureon (including Bydureon BCise) | Exenatide (extended release) | Once weekly | 2 mg | Type 2 diabetes in adults |
Both brands are marketed by AstraZeneca. Neither is approved for chronic weight management, which is the single most important thing to understand about exenatide brand names if you arrived here looking for a weight-loss drug.
Byetta: the twice-daily exenatide brand
Byetta was approved in 2005 and was the first GLP-1 receptor agonist to reach patients anywhere. It is injected under the skin twice a day, within 60 minutes before the morning and evening meals, and it is not taken after a meal. Treatment usually starts at 5 mcg twice daily, and the prescriber may increase to 10 mcg twice daily after about a month depending on response and tolerance.
Because it is short acting, Byetta works mainly on the glucose rise that follows a meal. That is a different profile from the once-weekly drugs most people know today, which hold a steadier level across the whole week.
One label detail worth knowing: Byetta does not carry the boxed warning about thyroid C-cell tumors that appears on the extended-release exenatide product and on several newer GLP-1 medicines. That difference sits in the labeling and is a question for your prescriber rather than a reason to prefer one product on your own.
Bydureon: the once-weekly exenatide brand
Bydureon is the same molecule in an extended-release formulation, given as a single 2 mg injection once a week on the same day each week. The convenience is obvious, and it was the first once-weekly GLP-1 receptor agonist, arriving years before the weekly semaglutide and tirzepatide products.
Bydureon carries a boxed warning for thyroid C-cell tumors observed in rodents, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Injection-site nodules are reported more often with the extended-release form than with the twice-daily one.
Availability of exenatide products has shifted over the years as the market moved toward newer agents. If you are trying to fill a prescription, confirm current availability with your pharmacy rather than assuming, because supply for older GLP-1 brands changes more often than for the market leaders.
Where exenatide came from
Exenatide has the most unusual origin story in the category. It is a synthetic version of exendin-4, a peptide found in the saliva of the Gila monster, a venomous lizard native to the southwestern United States. Exendin-4 turned out to resemble human GLP-1 closely enough to activate the same receptor, but it resists the enzyme that breaks natural GLP-1 down within minutes, which is why it lasts long enough to be a usable medicine.
That discovery is the foundation of the entire drug class. If you want the underlying biology, see what GLP-1 actually is and the wider GLP-1 receptor agonist drug class.
Exenatide brand names versus the newer GLP-1 brands
Exenatide is rarely the first choice today, and the reason is straightforward: the drugs that came after it work better on both blood sugar and body weight. Weight loss on exenatide is modest, generally a few kilograms, which was notable in 2005 and looks small beside what the current generation produces.
For scale, semaglutide 2.4 mg produced about 14.9 per cent mean body-weight loss over 68 weeks in the STEP-1 trial, and tirzepatide reached up to about 20.9 per cent over 72 weeks in SURMOUNT-1. Those are separate trials in different populations, and neither drug is exenatide, but the gap in magnitude is not subtle.
- Semaglutide is sold as Ozempic, Wegovy, and Rybelsus. See semaglutide brand names.
- Tirzepatide is sold as Mounjaro and Zepbound. See tirzepatide brand names.
- Liraglutide is sold as Victoza for diabetes and Saxenda for weight management, both daily injections.
- Dulaglutide is sold as Trulicity, a weekly injection for type 2 diabetes.
- Exenatide is sold as Byetta and Bydureon, the subject of this page.
The full regulatory map is in our list of FDA-approved GLP-1 medications, and the outcome comparison is in GLP-1 weight loss results by drug.
Side effects of the exenatide brands
Exenatide shares the class side-effect profile, and nausea is reported particularly often with the twice-daily form:
- Nausea, most common when starting or after a dose increase
- Vomiting and diarrhea
- Reduced appetite
- Injection-site reactions, including small nodules that are more frequent with the extended-release product
Pancreatitis is a labeled risk for the class. Exenatide is cleared by the kidneys, so it is generally not recommended in severe renal impairment, which is one of the clearer clinical differences between exenatide and some newer agents. Any decision about whether these drugs suit your kidney function belongs with a clinician who can see your labs.
Why people search for exenatide brand names
Most searches for exenatide brand names come from one of three situations. Someone has been handed a prescription for Byetta or Bydureon and wants to know what the ingredient is. Someone is reading about GLP-1 medications and hit a name they did not recognise. Or someone is comparing older and newer options because of cost or coverage.
In each case the useful answer is the same: exenatide is a genuine GLP-1 receptor agonist, it works through the same receptor as the drugs dominating the headlines, and the two brand names simply reflect a twice-daily and a once-weekly version of one molecule. Whether it is the right drug for a particular person is a clinical judgement that depends on their diabetes control, kidney function, other medications, and what their plan covers.
This article is educational and is not medical advice. Byetta and Bydureon are prescription medicines with boxed warnings, contraindications, and meaningful side effects. Only a licensed clinician can decide whether any GLP-1 medication is appropriate for you, at what dose, and for how long. Never start, stop, or switch a medication on your own, and confirm current availability and pricing with your pharmacy.
Scientific References
3 sources- 1
Drucker DJ
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Cell Metabolism · 27(4) · 2018PMID: 29617641
PubMed - 2
Wilding JPH, Batterham RL, Calanna S, et al.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
New England Journal of Medicine · 384(11) · 2021PMID: 33567185
PubMed - 3
U.S. Food and Drug Administration
Prescribing information
U.S. Food and Drug Administration · 2026
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
What are the brand names for exenatide?
The exenatide brand names are Byetta and Bydureon. Byetta is the twice-daily injection taken before the morning and evening meals, and Bydureon is the extended-release version given once weekly. Both contain exenatide, both are marketed by AstraZeneca, and both are approved for type 2 diabetes.
Is Byetta the same as Bydureon?
They contain the same active ingredient, exenatide, but they are not interchangeable. Byetta is immediate release and injected twice daily at 5 mcg or 10 mcg. Bydureon is extended release and injected once weekly at 2 mg. Only Bydureon carries the thyroid C-cell tumor boxed warning.
Is exenatide approved for weight loss?
No. Both exenatide brand names, Byetta and Bydureon, are approved for type 2 diabetes in adults, not for chronic weight management. Weight loss on exenatide is generally modest, a few kilograms, and considerably smaller than what semaglutide or tirzepatide produce in trials.
Is exenatide a GLP-1 medication?
Yes. Exenatide is a GLP-1 receptor agonist, and Byetta was the first drug in that class ever approved, in 2005. It activates the same receptor as semaglutide and liraglutide, but it comes from exendin-4, a peptide originally identified in Gila monster saliva.
What is the generic name for Byetta and Bydureon?
The generic, or nonproprietary, ingredient name for both is exenatide. Byetta is immediate-release exenatide and Bydureon is extended-release exenatide. Having a shared ingredient name does not mean an FDA-approved generic version of either brand is available to buy.
How does exenatide compare to Ozempic?
Both are GLP-1 receptor agonists, but Ozempic contains semaglutide and is generally more effective for blood sugar and weight. Exenatide is older, comes as twice-daily Byetta or weekly Bydureon, and is cleared by the kidneys, which limits its use in severe renal impairment.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.